CO6190610A2 - Nueva utilizacion terapeutica para el tratamiento de las leucemias - Google Patents
Nueva utilizacion terapeutica para el tratamiento de las leucemiasInfo
- Publication number
- CO6190610A2 CO6190610A2 CO09066898A CO09066898A CO6190610A2 CO 6190610 A2 CO6190610 A2 CO 6190610A2 CO 09066898 A CO09066898 A CO 09066898A CO 09066898 A CO09066898 A CO 09066898A CO 6190610 A2 CO6190610 A2 CO 6190610A2
- Authority
- CO
- Colombia
- Prior art keywords
- medicament
- treatment
- preparation
- leukemia
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Abstract
1.- Utilización del compuesto N-[2-(2,1,3-benzotiadiazol-5-ilamino)-6-(2,6-dicIorofenil)pirido[2,3-d]pirimidin-7-il]-N'-(1,1-dimetiletil)-urea, o un hidrato, una sal o un solvato de este, para la preparación de un medicamento destinado al tratamiento de las leucemias. 2.- Utilización del compuesto N-[2-(2,1,3-benzotiadiazol-5-ilamino)-6-(2,6-diclorofenil)pirido[2,3-d]pirimidin-7-il]-N'-(1,1-dimetiletil)-urea, o un hidrato, una sal o un solvato de este, para la preparación de un medicamento destinado al tratamiento de las leucemias mieloides. 3.- Utilización según la reivindicación 2, para la preparación de un medicamento destinado al tratamiento de las leucemias del tipo AML. 4.- Utilización según la reivindicación 3, para la preparación de un medicamento destinado al tratamiento de las leucemias del tipo AML en la que el medicamento esta destinado a utilizarse para la administración por vía intravenosa. 5.- Utilización según la reivindicación 3, para la preparación de un medicamento destinado al tratamiento de las leucemias del tipo AML en la que el medicamento esta destinado a utilizarse para la administración por vía oral. 6.- Utilización según la reivindicación 3, para la preparación de un medicamento destinado al tratamiento de las leucemias del tipo AML en la que el medicamento esta destinado a utilizarse para la administración por vía intravenosa y por vía oral. 7.- Utilización según la reivindicación 2, para la preparación de un medicamento destinado al tratamiento de las leucemias del tipo CML. 8.- Utilización según la reivindicación 7, para la preparación de un medicamento destinado al tratamiento de las leucemias del tipo CML en la que el medicamento esta destinado a utilizarse para la administración por vía intravenosa. 9.- Utilización según la reivindicación 7, para la preparación de un medicamento destinado al tratamiento de las leucemias del tipo CML en la que el medicamento esta destinado a utilizarse para la administración por vía oral. 10.- Utilización según la reivindicación 7, para la preparación de un medicamento destinado al tratamiento de las leucemias del tipo CML en la que el medicamento esta destinado a utilizarse para la administración por vía intravenosa y por vía oral.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0611492A FR2910813B1 (fr) | 2006-12-28 | 2006-12-28 | Nouvelle utilisation therapeutique pour le traitement des leucemies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6190610A2 true CO6190610A2 (es) | 2010-08-19 |
Family
ID=38268928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO09066898A CO6190610A2 (es) | 2006-12-28 | 2009-06-26 | Nueva utilizacion terapeutica para el tratamiento de las leucemias |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US8236811B2 (es) |
| EP (1) | EP2107906B1 (es) |
| JP (1) | JP5317987B2 (es) |
| KR (1) | KR101458233B1 (es) |
| CN (1) | CN101568338B (es) |
| AR (1) | AR064550A1 (es) |
| AT (1) | ATE534392T1 (es) |
| AU (1) | AU2007347370B2 (es) |
| BR (1) | BRPI0720963A2 (es) |
| CA (1) | CA2672716C (es) |
| CL (1) | CL2007003846A1 (es) |
| CO (1) | CO6190610A2 (es) |
| CR (1) | CR10881A (es) |
| CY (1) | CY1112443T1 (es) |
| DK (1) | DK2107906T3 (es) |
| EA (1) | EA016873B1 (es) |
| EC (1) | ECSP099449A (es) |
| ES (1) | ES2377843T3 (es) |
| FR (1) | FR2910813B1 (es) |
| GT (1) | GT200900168A (es) |
| HK (1) | HK1138189A1 (es) |
| HR (1) | HRP20120170T1 (es) |
| JO (1) | JO2748B1 (es) |
| MA (1) | MA31100B1 (es) |
| MX (1) | MX2009007054A (es) |
| MY (1) | MY148515A (es) |
| NI (1) | NI200900129A (es) |
| NO (1) | NO20092496L (es) |
| NZ (1) | NZ577991A (es) |
| PE (1) | PE20081548A1 (es) |
| PL (1) | PL2107906T3 (es) |
| PT (1) | PT2107906E (es) |
| RS (1) | RS52162B (es) |
| SI (1) | SI2107906T1 (es) |
| SV (1) | SV2009003315A (es) |
| TN (1) | TN2009000234A1 (es) |
| TW (1) | TWI433678B (es) |
| UA (1) | UA97505C2 (es) |
| WO (1) | WO2008102075A2 (es) |
| ZA (1) | ZA200904478B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2948568B1 (fr) | 2009-07-30 | 2012-08-24 | Sanofi Aventis | Formulation pharmaceutique |
| EP2638911A1 (en) | 2012-03-14 | 2013-09-18 | Sanofi | Novel combinations for treating acute myeloid leukaemia or chronic myeloid leukaemia |
| AR098716A1 (es) * | 2013-12-13 | 2016-06-08 | Novartis Ag | Formas de dosificación farmacéuticas |
| US20230136218A1 (en) * | 2019-09-23 | 2023-05-04 | President And Fellows Of Harvard College | Methods and compositions for treating acute myeloid leukemia |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1171218A (en) | 1967-11-09 | 1969-11-19 | Parke Davis & Co | New Heterocyclic Amine Compounds and Methods for their Production |
| EP0790997B1 (en) | 1994-11-14 | 2000-03-22 | Warner-Lambert Company | 6-ARYL PYRIDO[2,3-d]PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION |
| IL115256A0 (en) | 1994-11-14 | 1995-12-31 | Warner Lambert Co | 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use |
| US5620981A (en) | 1995-05-03 | 1997-04-15 | Warner-Lambert Company | Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
| IL117923A (en) | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
| AU7315700A (en) | 1999-09-20 | 2001-04-24 | Takeda Chemical Industries Ltd. | Melanin concentrating hormone antagonist |
| AP2002002586A0 (en) | 2000-01-25 | 2002-09-30 | Warner Lambert Co | Pyrido[2,3-d] pyrimidine-2,7-diamine kinase inhibitors. |
| IL151480A0 (en) | 2000-03-06 | 2003-04-10 | Warner Lambert Co | 5-alkylpyrido[2,3-d] pyrimidines tyrosine kinase inhibitors |
| EP1307450B1 (en) | 2000-08-04 | 2008-09-17 | Warner-Lambert Company LLC | 2-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido(2,3-d)pyrimidin-7-ones |
| US20030105115A1 (en) * | 2001-06-21 | 2003-06-05 | Metcalf Chester A. | Novel pyridopyrimidines and uses thereof |
| WO2004063195A1 (en) | 2003-01-03 | 2004-07-29 | Sloan-Kettering Institute For Cancer Research | Pyridopyrimidine kinase inhibitors |
| TW200502236A (en) | 2003-03-28 | 2005-01-16 | Hoffmann La Roche | Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents |
| WO2005105097A2 (en) | 2004-04-28 | 2005-11-10 | Gpc Biotech Ag | Pyridopyrimidines for treating inflammatory and other diseases |
| FR2873118B1 (fr) | 2004-07-15 | 2007-11-23 | Sanofi Synthelabo | Derives de pyrido-pyrimidine, leur application en therapeutique |
| UY29017A1 (es) | 2004-07-16 | 2006-02-24 | Boehringer Ingelheim Int | Inhibidores de polimerasa viral |
| FR2887882B1 (fr) * | 2005-07-01 | 2007-09-07 | Sanofi Aventis Sa | Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique |
| FR2896246B1 (fr) | 2006-01-13 | 2008-08-15 | Sanofi Aventis Sa | Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique. |
-
2006
- 2006-12-28 FR FR0611492A patent/FR2910813B1/fr not_active Expired - Fee Related
-
2007
- 2007-12-24 TW TW096149811A patent/TWI433678B/zh not_active IP Right Cessation
- 2007-12-27 AU AU2007347370A patent/AU2007347370B2/en not_active Ceased
- 2007-12-27 CA CA2672716A patent/CA2672716C/fr not_active Expired - Fee Related
- 2007-12-27 SI SI200730860T patent/SI2107906T1/sl unknown
- 2007-12-27 UA UAA200907941A patent/UA97505C2/ru unknown
- 2007-12-27 BR BRPI0720963-0A patent/BRPI0720963A2/pt active Search and Examination
- 2007-12-27 NZ NZ577991A patent/NZ577991A/en not_active IP Right Cessation
- 2007-12-27 AR ARP070105919A patent/AR064550A1/es not_active Application Discontinuation
- 2007-12-27 EP EP07872446A patent/EP2107906B1/fr active Active
- 2007-12-27 EA EA200970639A patent/EA016873B1/ru not_active IP Right Cessation
- 2007-12-27 ZA ZA200904478A patent/ZA200904478B/xx unknown
- 2007-12-27 PL PL07872446T patent/PL2107906T3/pl unknown
- 2007-12-27 AT AT07872446T patent/ATE534392T1/de active
- 2007-12-27 MX MX2009007054A patent/MX2009007054A/es active IP Right Grant
- 2007-12-27 PT PT07872446T patent/PT2107906E/pt unknown
- 2007-12-27 JP JP2009543501A patent/JP5317987B2/ja not_active Expired - Fee Related
- 2007-12-27 CN CN2007800482286A patent/CN101568338B/zh not_active Expired - Fee Related
- 2007-12-27 WO PCT/FR2007/002171 patent/WO2008102075A2/fr active Application Filing
- 2007-12-27 ES ES07872446T patent/ES2377843T3/es active Active
- 2007-12-27 CL CL2007003846A patent/CL2007003846A1/es unknown
- 2007-12-27 MY MYPI20092747A patent/MY148515A/en unknown
- 2007-12-27 RS RS20120061A patent/RS52162B/en unknown
- 2007-12-27 JO JO2007563A patent/JO2748B1/en active
- 2007-12-27 KR KR1020097013456A patent/KR101458233B1/ko not_active IP Right Cessation
- 2007-12-27 DK DK07872446.5T patent/DK2107906T3/da active
-
2008
- 2008-01-02 PE PE2008000043A patent/PE20081548A1/es not_active Application Discontinuation
-
2009
- 2009-06-08 TN TNP2009000234A patent/TN2009000234A1/fr unknown
- 2009-06-16 US US12/485,401 patent/US8236811B2/en not_active Expired - Fee Related
- 2009-06-16 GT GT200900168A patent/GT200900168A/es unknown
- 2009-06-22 EC EC2009009449A patent/ECSP099449A/es unknown
- 2009-06-22 CR CR10881A patent/CR10881A/es not_active Application Discontinuation
- 2009-06-24 SV SV2009003315A patent/SV2009003315A/es active IP Right Grant
- 2009-06-26 NI NI200900129A patent/NI200900129A/es unknown
- 2009-06-26 CO CO09066898A patent/CO6190610A2/es active IP Right Grant
- 2009-07-02 NO NO20092496A patent/NO20092496L/no not_active Application Discontinuation
- 2009-07-16 MA MA32101A patent/MA31100B1/fr unknown
-
2010
- 2010-04-14 HK HK10103640.6A patent/HK1138189A1/xx not_active IP Right Cessation
-
2012
- 2012-02-21 HR HR20120170T patent/HRP20120170T1/hr unknown
- 2012-02-23 CY CY20121100183T patent/CY1112443T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2622559T3 (es) | Combinación terapéutica que comprende un inhibidor de cdk y un agente antineoplásico | |
| CR10419A (es) | Derivados de Pirazolo [3,4-D]-Pirimidina útiles para tratar trastornos respiratorios | |
| UY27875A1 (es) | Prodrogas 2 ' y 3 ' de nucleósidos modificados para tratar flaviviridae | |
| BRPI0611705A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de composto | |
| UY29085A1 (es) | Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes | |
| PE20180203A1 (es) | Procedimiento para la preparacion de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificacion para su uso como principio activo farmaceutico | |
| UY30819A1 (es) | Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
| EP1749830A4 (en) | CURCUMOL DERIVATIVES, COMPOSITION COMPRISING THE SAME, AND THEIR USE FOR THE PRODUCTION OF MEDICAMENTS | |
| AR062392A1 (es) | Uso de compuestos y derivados de 2,5 dihidroxibenceno para el tratamiento de rosacea | |
| AR054347A1 (es) | Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| BR112015029401A2 (pt) | derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças | |
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| AR074240A1 (es) | Compuesto 3-(4-cloro-2-fluorobencil )-2-metil-n-(5- metil-1h- pirazol-3-il)-8- (morfolinometil)imidazo (1,2-b)piridazin -6-amina o una sal farmaceuticamente aceptable del mismo, su uso para preparar un medicamento util para el tratamiento de trastornos mieloproliferantes cronicos y condiciones asoci | |
| AR077125A1 (es) | Combinaciones farmaceuticas utiles para tratar el vhc | |
| BR112012026480A2 (pt) | combinações contendo 2,3-di-hidroimidazo[1,2-c]quinazolina substituída | |
| AR062393A1 (es) | Uso de derivado del 2.5-dihidrixibenceno para el tratamiento de artritis y dolor | |
| RU2018134167A (ru) | Комбинированная терапия для лечения острого миелоидного лейкоза | |
| CO6190610A2 (es) | Nueva utilizacion terapeutica para el tratamiento de las leucemias | |
| CL2021003034A1 (es) | Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton | |
| AR117614A1 (es) | Forma de dosificación farmacéutica administrable por vía oral con liberación modificada | |
| AR064543A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| ECSP21003707A (es) | Forma de dosificación farmacéutica administrable por vía oral con liberación modificada | |
| ES2656913T3 (es) | Endrogenina A y agentes antineoplásicos para el tratamiento de tumores quimiosensibles o quimiorresistentes | |
| ECSP077843A (es) | Tratamiento o prevención del prurito |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |